The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

Fusion biopsy and patient follow-up with 3D mapping are the cornerstone of a successful Focal Therapy program. In line with ...

Adagio Medical Holdings, Inc. , a leading innovator in catheter ablation technologies, provided updates today on the progress in its streamlined focus on leadership in ventricular tachycardia ("VT") ...

is an early commercial stage medical device company located in Laguna Hills, California focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous ...

Boulder iQ executives will be presenting novel ways for medical device developers to speed their products to market at this week's LSI USA 25 Emerging MedTech Summit in Dana Point, California. Jim ...

Proving your product to be safe and effective while also getting buy-in from the healthcare ecosystem are only some of the ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most ...

By using AI to measure the size of a man's prostate tumor more precisely, we can better predict who is likely to be cured with focal therapies like partial gland cryoablation." Dr. Wayne Brisbane ...

According to Research by SNS Insider, The Pulsed Field Ablation Market Growth is Driven by Technological Advancements and Rising Prevalence of Atrial FibrillationPune, March 20, 2025 (GLOBE NEWSWIRE) ...